Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201 - Business Wire

Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201  Business Wire

Novus Therapeutics announces that it has dosed the first patients in a phase 2a trial of OP0201, the lead product candidate for otitis media.